Mikko Gynther

Sex-specific changes in protein expression of membrane transporters in the brain cortex of 5xFAD mouse model of Alzheimer’s disease

Puris, Elena; Saveleva, Liudmila; Auriola, Seppo; Gynther, Mikko; Kanninen, Katja M; Fricker, Gert. 2024. Frontiers in pharmacology. 15: . 1365051 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

In vitro identification of decreased function phenotype ABCG2 variants

Suominen, Laura; Sjöstedt, Noora; Vellonen, Kati-Sisko; Gynther, Mikko; Auriola, Seppo; Kidron, Heidi. 2023. European journal of pharmaceutical sciences. 188: A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Metabolomic, Lipidomic and Proteomic Characterisation of Lipopolysaccharide-induced Inflammation Mouse Model

Puris, Elena; Kouřil, Štěpán; Najdekr, Lukáš; Auriola, Seppo; Loppi, Sanna; Korhonen, Paula; Gómez-Budia, Mireia; Fricker, Gert; Kanninen, Katja M; Malm, Tarja; Friedecký, David; Gynther, Mikko. 2022. Neuroscience. 496: 165-178 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Systemic inflammation elevates cytosolic prolyl oligopeptidase protein expression but not peptidase activity in the cerebral cortices of familial Alzheimer`s disease modeling mice

Puris, Elena; Jalkanen, Aaro; Auriola, Seppo; Loppi, Sanna; Korhonen, Paula; Kanninen, Katja M.; Malm, Tarja; Koistinaho, Jari; Gynther, Mikko. 2022. Brain disorders. 6: A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels

Montaser, Ahmed; Lehtonen, Marko; Gynther, Mikko; Huttunen, Kristiina. 2020. Pharmaceutics. 12: 344 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-Type amino acid transporter 1 as a target for drug delivery

Puris, Elena; Gynther, Mikko; Auriola, Seppo; Huttunen, Kristiina. 2020. Pharmaceutical research. 37: 88 A2 Katsausartikkeli tieteellisessä aikakauslehdessä

L-Type Amino Acid Transporter 1 (LAT1)-Utilizing Prodrugs Are Carrier-Selective Despite Having Low Affinity for Organic Anion Transporting Polypeptides (OATPs)

Huttunen, Johanna; Gynther, Mikko; Vellonen, KatiSisko; Huttunen, Kristiina M. 2019. International journal of pharmaceutics. 571: 118714 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia

Huttunen J, Peltokangas S, Gynther M, Natunen T, Hiltunen M, Auriola S, Ruponen M, Vellonen KS, Huttunen KM. 2019. Scientific reports. 9: 12860 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery

Puris, E; Gynther, M; Huttunen, J; Auriola, S; Huttunen, KM. 2019. European journal of pharmaceutical sciences. 129: 99-109 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates

Puris, E; Pasanen, M; Ranta, VP; Gynther, M; Petsalo, A; Käkelä, P; Männistö, V; Pihlajamäki, J. 2019. Basic and clinical pharmacology and toxicology. 125: 123-132 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets

Puris, Elena; Gynther, Mikko; de Lange, Elizabeth C M; Auriola, Seppo; Harnmarlund-Udenaes, Margareta; Huttunen, Kristiina M; Loryan, Irena. 2019. Molecular pharmaceutics. 16: 3261-3274 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson's Disease

Zhurakovskaya, Ekaterina; Leikas, Juuso; Pirttimäki, Tiina; Casas Mon, Francesc; Gynther, Mikko; Aliev, Rubin; Rantamäki, Tomi; Tanila, Heikki; Forsberg, Markus M; Gröhn, Olli; Paasonen, Jaakko; Jalkanen, Aaro J. 2019. eNeuro. 6: 1-12 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands : Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation

Brogi, Simone; Brindisi, Margherita; Butini, Stefania; Kshirsagar, Giridhar U.; Maramai, Samuele; Chemi, Giulia; Gemma, Sandra; Campiani, Giuseppe; Novellino, Ettore; Fiorenzani, Paolo; Pinassi, Jessica; Alois, Anna Maria; Gynther, Mikko; Venskutonyte, Raminta; Han, Liwei; Frydenvang, Karla; Kastrup, Jette Sandholm; Pickering, Darryl S. 2018. Journal of medicinal chemistry. 61: 2124-2130 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes

Gynther, Mikko; Puris, Elena; Peltokangas, Soile; Auriola, Seppo; Kanninen, Katja M; Koistinaho, Jari; Huttunen, Kristiina M; Ruponen, Marika; Vellonen, Kati-Sisko. 2018. Pharmaceutical research. 2019; 36: 17 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Extracellular Prolyl Oligopeptidase Derived from Activated Microglia is a Potential Neuroprotection Target.

Natunen, Teemu A; Gynther, Mikko; Rostalski, Hannah; Jaako, Külli; Jalkanen, Aaro J. 2018. Basic and clinical pharmacology and toxicology. 2019; 124: 40-49 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Structural properties for selective and efficient L-type amino acid transporter 1 (LAT1) mediated cellular uptake

Kärkkäinen, J; Gynther, M; Kokkola, T; Petsalo, A; Auriola, S; Lahtela-Kakkonen, M; Laine, K; Rautio, J; Huttunen, KM. 2018. International journal of pharmaceutics. 544: 91-99 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Targeted efflux transporter inhibitors - a solution to improve poor cellular accumulation of anti-cancer agents

Huttunen, J; Gynther, M; Huttunen, KM. 2018. International journal of pharmaceutics. 550: 278-289 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist

Gynther M, Proietti Silvestri I, Hansen JC, Hansen KB, Malm T, Ishchenko Y, Larsen Y, Han L, Kayser S, Auriola S, Petsalo A, Nielsen B, Pickering DS, Bunch L. 2017. Journal of medicinal chemistry. 60: 9885-9904 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease

Vellonen KS, Ihalainen J, Boucau M-C, Gosselet F, Picardat T, Gynther M, Kanninen KM, White AR, Malm T, Koistinaho J, Forsberg MM, Ruponen M. 2017. Pharmaceutical research. 34: 2652-2662 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Effects of Dimeric PSD-95 Inhibition on Excitotoxic Cell Death and Outcome After Controlled Cortical Impact in Rats

Sommer JB, Bach A, Malá H, Gynther M, Bjerre AS, Gram MG, Marschner L, Strømgaard K, Mogensen J, Pickering DS. 2017. Neurochemical research. 42: 3401-3413 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-type amino acid transporter 1 utilizing prodrugs : how to achieve effective brain delivery and low systemic exposure of drugs

Puris E, Gynther M, Huttunen J, Petsalo A, Huttunen KM. 2017. Journal of controlled release. 261: 93-104 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells

Huttunen Kristiina M, Gynther Mikko, Huttunen Johanna, Puris Elena, Spicer Julie A, Denny William A. 2016. Journal of medicinal chemistry. 59: 5740-5751 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine

Puris Elena, Pasanen Markku, Gynther Mikko, Häkkinen Merja R, Pihlajamäki Jussi, Keränen Tapani, Honkakoski Paavo, Raunio Hannu, Petsalo Aleksanteri. 2016. Analytical and bioanalytical chemistry. 2017; 409: 251-268 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure

Gynther Mikko, Peura Lauri, Vernerová Monika, Leppänen Jukka, Kärkkäinen Jussi, Lehtonen Marko, Rautio Jarkko, Huttunen Kristiina M. 2016. Neurochemical research. 41: 2797-2809 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102

Haym Isabell, Huynh Tri H V, Hansen Stinne W, Pedersen Martin H F, Ruiz Josep A, Erichsen Mette N, Gynther Mikko, Bjørn-Yoshimoto Walden E, Abrahamsen Bjarke, Bastlund Jesper F, Bundgaard Christoffer, Eriksen Anette L, Jensen Anders A, Bunch Lennart. 2016. Chemmedchem. 11: 403-419 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Effects of the dimeric PSD-95 inhibitor UCCB01-144 in mouse models of pain, cognition and motor function

Andreasen Jesper T, Nasser Arafat, Caballero-Puntiverio Maitane, Sahlholt Maj, Bach Anders, Gynther Mikko, Strømgaard Kristian, Pickering Darryl S. 2016. European journal of pharmacology. 780: 166-173 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

In vivo characterization of the ultrapotent monoacylglycerol lipase inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl} (1H-1,2,4-triazol-1-yl)methanone (JJKK-048)

Aaltonen Niina, Kedzierska Ewa, Orzelska-Gorka Jolanta, Lehtonen Marko, Navia-Paldanius Dina, Jakupovic Hermina, Savinainen Juha, Nevalainen Tapio, Laitinen Jarmo T, Parkkari Teija, Gynther Mikko. 2016. Journal of pharmacology and experimental therapeutics. 359: 62-72 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs

Gynther Mikko, Pickering Darryl S, Spicer Julie A, Denny William A, Huttunen Kristiina M. 2016. Molecular pharmaceutics. 13: 2484-2491 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

L-type Amino Acid Transporter 1 (LAT1)-Mediated Targeted Delivery of Perforin Inhibitors

Huttunen Kristiina M, Huttunen Johanna, Aufderhaar Imke, Gynther Mikko, Denny William A, Spicer Julie A. 2015. International journal of pharmaceutics. 498 (2016): 205-216 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Aihiolääketeknologia lääkekehityksessä

Rautio Jarkko, Huttunen Kristiina, Gynther Mikko, Laine Krista, Leppänen Jukka, Kärkkäinen Jussi, Malmioja Kalle. 2014. Dosis. 30: 209 B1 Kirjoitus tieteellisessä aikakauslehdessä

Amino acid ester prodrugs conjugated to the alpha-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1)

Rautio Jarkko, Kärkkäinen Jussi, Huttunen Kristiina, Gynther Mikko. 2014. European journal of pharmaceutical sciences. 2015; 66: 36-40 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid

Gynther Mikko, Petsalo Aleksanteri, Hansen Steen H, Bunch Lennart, Pickering Darryl S. 2014. Neurochemical research. 2015; 40: 542-549 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma

Gynther Mikko, Kääriäinen Tiina M, Hakkarainen Jenni J, Jalkanen Aaro J, Petsalo Aleksanteri, Lehtonen Marko, Peura Lauri, Kurkipuro Jere, Samaranayake Haritha, Yla-Herttuala Seppo, Rautio Jarkko, Forsberg Markus M. 2014. Drug metabolism and disposition. 2015; 43: 140-146 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth

Ramirez Yulian P, Mladek Ann C, Phillips Roger M, Gynther Mikko, Rautio Jarkko, Ross Alonzo H, Wheelhouse Richard T, Sakaria Jann N. 2014. Molecular cancer therapeutics. 2015; 14: 111-119 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors

Patel Jayendra Z, Nevalainen Tapio J, Savinainen Juha R, Adams Yahaya, Laitinen Tuomo, Runyon Robert S, Vaara Miia, Ahenkorah Stephen, Kaczor Agnieszka A, Navia-Paldanius Dina, Gynther Mikko, Aaltonen Niina, Joharapurkar Amit A, Jain Mukul R, Haka Abigail S, Maxfield Frederick R, Laitinen Jarmo T, Parkkari Teija. 2014. Chemmedchem. 2015; 10: 253-265 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Quantitative Insight into the Design of Compounds Recognized by the L-Type Amino Acid Transporter 1 (LAT1)

Ylikangas Henna, Malmioja Kalle, Peura Lauri, Gynther Mikko, Nwachukwu Emmanuel O, Leppänen Jukka, Laine Krista, Rautio Jarkko, Lahtela-Kakkonen Maija, Huttunen Kristiina M, Poso Antti. 2014. Chemmedchem. 9: 2699-2707 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine

Peura Lauri, Malmioja Kalle, Huttunen Kristiina, Leppänen Jukka, Hämäläinen Miia, Forsberg Markus M, Gynther Mikko, Rautio Jarkko, Laine Krista. 2013. Pharmaceutical research. 30: 2523-2537 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests

Andreasen JT, Gynther M, Rygaard A, Bøgelund T, Nielsen SD, Clausen RP, Mogensen J, Pickering DS. 2013. Neuroscience letters. 546: 6-10 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?

Rautio Jarkko, Gynther Mikko, Laine Krista. 2013. Therapeutic delivery. 4: 281-284 B1 Kirjoitus tieteellisessä aikakauslehdessä

UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801

Andreasen Jesper T, Bach Anders, Gynther Mikko, Nasser Arafat, Mogensen Jesper, Strømgaard Kristian, Pickering Darryl S. 2013. Neuropharmacology. 67: 193-200 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery

Peura Lauri, Malmioja Kalle, Laine Krista, Leppänen Jukka, Gynther Mikko, Isotalo Antti, Rautio Jarkko. 2011. Molecular pharmaceutics. 8: 1857-1866 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

New Prodrug Design Ideas for Transporter-Mediated CNS Drug Delivery

Kalle Malmioja, Lauri Peura, Krista Laine, Jukka Leppänen, Mikko Gynther, Jarkko Rautio. 2011.

New Prodrug Desing Ideas for Large Amino Acid Transporter 1 -Mediated Drug Brain Delivery

Peura L, Malmioja K, Laine K, Leppänen J, Gynther M & Rautio J. 2011.

Blood-Brain Barrier Transporters in CNS Drug Delivery: Design and Biological Evaluation of LAT1 and GluT1 -Targeted Prodrugs

Gynther Mikko. 2010. Publications of the University of Eastern Finland. Dissertations in Health Sciences G5 Artikkeliväitöskirja

Brain uptake of ketoprofen-lysine prodrug in rats

Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppänen J, Knuuti J & Rautio J. 2010. International journal of pharmaceutics. 399: 121-128 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats

Gynther M, Ropponen J, Laine K, Leppänen J, Haapakoski P, Peura L, Järvinen T, Rautio J. 2009. Journal of medicinal chemistry. 52: 3348-3353 A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Tarkenna hakuasi

Tutkimusryhmät

Sex-specific changes in protein expression of membrane transporters in the brain cortex of 5xFAD mouse model of Alzheimer’s disease

In vitro identification of decreased function phenotype ABCG2 variants

Metabolomic, Lipidomic and Proteomic Characterisation of Lipopolysaccharide-induced Inflammation Mouse Model

Systemic inflammation elevates cytosolic prolyl oligopeptidase protein expression but not peptidase activity in the cerebral cortices of familial Alzheimer`s disease modeling mice

L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels

L-Type amino acid transporter 1 as a target for drug delivery

L-Type Amino Acid Transporter 1 (LAT1)-Utilizing Prodrugs Are Carrier-Selective Despite Having Low Affinity for Organic Anion Transporting Polypeptides (OATPs)

L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia

L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery

Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates

Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets

Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson's Disease

(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands : Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation

Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes

Extracellular Prolyl Oligopeptidase Derived from Activated Microglia is a Potential Neuroprotection Target.

Structural properties for selective and efficient L-type amino acid transporter 1 (LAT1) mediated cellular uptake

Targeted efflux transporter inhibitors - a solution to improve poor cellular accumulation of anti-cancer agents

Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist

Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease

Effects of Dimeric PSD-95 Inhibition on Excitotoxic Cell Death and Outcome After Controlled Cortical Impact in Rats

L-type amino acid transporter 1 utilizing prodrugs : how to achieve effective brain delivery and low systemic exposure of drugs

A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells

A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine

Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure

Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102

Effects of the dimeric PSD-95 inhibitor UCCB01-144 in mouse models of pain, cognition and motor function

In vivo characterization of the ultrapotent monoacylglycerol lipase inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl} (1H-1,2,4-triazol-1-yl)methanone (JJKK-048)

Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs

L-type Amino Acid Transporter 1 (LAT1)-Mediated Targeted Delivery of Perforin Inhibitors

Aihiolääketeknologia lääkekehityksessä

Amino acid ester prodrugs conjugated to the alpha-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1)

Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid

Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors

Quantitative Insight into the Design of Compounds Recognized by the L-Type Amino Acid Transporter 1 (LAT1)

Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine

Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests

LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?

UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801

Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery

New Prodrug Design Ideas for Transporter-Mediated CNS Drug Delivery

New Prodrug Desing Ideas for Large Amino Acid Transporter 1 -Mediated Drug Brain Delivery

Blood-Brain Barrier Transporters in CNS Drug Delivery: Design and Biological Evaluation of LAT1 and GluT1 -Targeted Prodrugs

Brain uptake of ketoprofen-lysine prodrug in rats

Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats

Enhanced brain drug delivery and targeting

Large neutral amino acid transporter enables brain drug delivery via prodrugs

Prodrug approaches for CNS delivery